ASND

Ascendis Pharma A/S (ASND) | Rumor.io

Ascendis Pharma A/S

ASND

Attention (50-day avg)0%

Attention rank (50-day avg)#1,172

Bullish sentiment (50-day avg)95%

Price to earnings ratio17.6

Market capitalization15.1B

Earnings per share12.8

Dividend yield (TTM)—

Revenue (annual)720.1M

Net income (annual)-228M

Social

What share of all stock conversation is about ASND?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% -0.02

Aug 31

Ascendis Pharma A/S ($ASND) has settled a global patent dispute with BioMarin Pharmaceutical ($BMRN) over the achondroplasia drug Yuviwel, with Ascendis agreeing to pay royalties to BioMarin on Yuviwel sales in the U.S., EU, Brazil, and South Korea.
The settlement was announced on Sunday, and Ascendis Pharma stock ($ASND) has risen by around 7% following the news, with some analysts maintaining their Buy ratings and price targets, including HC Wainwright & Co. with a target of $344.
Ascendis will pay BioMarin royalties of 20% on U.S. sales and 18% in the EU, Brazil, and South Korea until 2030, as part of the global settlement agreement.

Generated by AI

Sentiment

Of the messages about ASND that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% new	88.89% -11.11	84.66% -15.25
Bearish	—	0% -100	11.11% +11.11	15.34% +15.25

Bullish· Sep 2

Ascendis Pharma A/S ($ASND) has been upgraded by JP Morgan to Overweight with a price target of 165.
The company's low float and upcoming app drop make it a strong buy opportunity.
Ascendis Pharma A/S is considered a sleeper rocket with significant potential for growth.

Bearish· Apr 3

Ascendis Pharma's ($ASND) stock has plummeted ~35% after the FDA found deficiencies in its TransCon application.
The FDA's negative statement has led to a significant sell-off, with some investors even questioning the 40% drop in value.
The company may need to raise cash in the near future due to the potential delay of its TransCon filing by at least a year or two.

Generated by AI

Topics

Of the messages about ASND that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	99.76%	79.01%
Analysts	—	0%	0%	7.74%
Earnings	—	0%	0%	3.66%
Technical Analysis	—	0%	0.24%	7.26%
Controversies	—	0%	0%	0.74%
Macro	—	0%	0%	1.59%

Earnings· Aug 29

Ascendis Pharma A/S reported a Q2 loss of $0.66, beating consensus estimates of a $1.03 loss.
The company reported Q2 GAAP EPS loss of €0.55 and revenue of €0.018M, a slight increase from €0.44M in Q2 2017.
$ASND stock dropped 1.20% following the release of Q2 results.

Analysts· Mar 15

Morgan Stanley raised Ascendis Pharma's price target to $197 from $180, maintaining an Overweight rating.
Bank of America upgraded Ascendis Pharma to Buy from Neutral, raising the price target to $161 from $148.
SVB Leerink analyst Joseph Schwartz raised the price target for Ascendis Pharma to $193 from $190, maintaining an Outperform rating.

Announcements· Sep 16

Ascendis Pharma's (ASND) TransCon trial achieved its primary objective, leading to a significant stock price increase.
The trial demonstrated that TransCon CNP (Navepegritide) showed superior results compared to a placebo, marking a crucial milestone for the company.
The pivotal ApproaCH trial's success has triggered a substantial pre-market price surge, with ASND stock rising by over 19% in early trading.

Generated by AI

Community

Of the messages about ASND, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	4%	33.91%	78.39%	72.8%
Newcomers	96%	66.09%	21.61%	27.2%

Regulars· Aug 17

The focus is on Druck's investment strategy, specifically his approach to biotech stocks like ASND.
Regulars are sharing their observations on Druck's track record, highlighting his strong performance in biotech investments.
One regular took a position in ASND before the launch metrics started to inflect, suggesting a positive outlook on the stock.

Newcomers· Feb 28

The FDA has approved Ascendis Pharma's (ASND) weekly therapy, Yuviwel, for pediatric achondroplasia, a rare form of dwarfism.
The approval is a major catalyst for ASND, with expected volatility and a potential increase in options flow.
ASND's approval is also being closely watched in the biotech sector, particularly with related stocks such as BBIO, as sector rotation and support levels are being monitored.

Generated by AI

On September 14, Ascendis Pharma A/S (NASDAQ:ASND) said its Board had authorized buying back up to $400 million of its own ordinary shares. That is a striking move from a company that lost money in the second quarter of 2025. Here is what stands behind the announcement, and what the fine print does and does […]

9d agoYahoo Finance

Ascendis Pharma (ASND) Regains Exclusive Rights To Key TransCon Metabolic Programs

11d agoYahoo Finance

Ascendis Pharma (ASND) Will Regain Metabolic Drug Rights. Is Greater Ownership Worth the Cost?

Ascendis Pharma A/S (NASDAQ:ASND) announced on September 14 that it will regain exclusive rights to develop, manufacture, and commercialize TransCon products in metabolic and cardiovascular diseases following the termination of its collaboration with Novo Nordisk A/S (NYSE:NVO). The rights include once-monthly TransCon Semaglutide, an investigational long-acting prodrug of semaglutide intended for obesity and type 2 […]

12d agoYahoo Finance

Ascendis Pharma: Back To Full Independence (NASDAQ:ASND)

Ascendis Pharma faces negative sentiment after Novo returned TransCon rights, compounding prior partner exits and disappointments. Read more on ASND stock here.

13d agoSeeking Alpha

Ascendis Has Capacity To Execute Alone After Termination of Novo Nordisk Collaboration, Wedbush Says

Ascendis Pharma (ASND) share selloff on Tuesday after the termination of its collaboration agreement

13d agoYahoo Finance

H.C. Wainwright reiterates Ascendis Pharma stock rating on Novo deal end

13d agoInvesting.com

Also Discussed

Investors talking about ASND also mention

#	Name	Attention
1	BioMarin Pharmaceutical IncBMRN	0%+0
2	Crinetics Pharmaceuticals IncCRNX	0%0
3	BridgeBio Pharma Inc.BBIO	0%-0.02
4	SWTX - SpringWorks Therapeutics, Inc.	——
5	Rhythm Pharmaceuticals, Inc.RYTM	0%0
6	Biohaven Ltd.BHVN	0%-0.01
7	Genmab A/S American Depositary SharesGMAB	0%0
8	BPMC - Blueprint Medicines Corporation	——
9	Maravai LifeSciences Holdings, Inc. Class A Common StockMRVI	0%new
10	Vera Therapeutics Inc.VERA	0%new

Ascendis Pharma A/S

Healthcare
Biotechnology

Ascendis Pharma A/S is a global biopharmaceutical company focused on developing and commercializing therapies for rare endocrine diseases and other serious chronic conditions. The company uses its proprietary TransCon technology platform to create medicines designed to improve treatment delivery and address unmet medical needs. Its current portfolio includes marketed products for growth hormone deficiency and chronic hypoparathyroidism, along with clinical-stage programs in endocrinology rare disease and oncology. Headquartered in Copenhagen, Denmark, Ascendis Pharma operates across Europe and the United States, combining research, development, and commercialization capabilities to support patients, physicians, and healthcare systems in specialized therapeutic areas.

Website

Location

Tuborg Boulevard 12

Hellerup, 2900

Denmark

Social

What share of all stock conversation is about ASND?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% -0.02

Aug 31

Ascendis Pharma A/S ($ASND) has settled a global patent dispute with BioMarin Pharmaceutical ($BMRN) over the achondroplasia drug Yuviwel, with Ascendis agreeing to pay royalties to BioMarin on Yuviwel sales in the U.S., EU, Brazil, and South Korea.
The settlement was announced on Sunday, and Ascendis Pharma stock ($ASND) has risen by around 7% following the news, with some analysts maintaining their Buy ratings and price targets, including HC Wainwright & Co. with a target of $344.
Ascendis will pay BioMarin royalties of 20% on U.S. sales and 18% in the EU, Brazil, and South Korea until 2030, as part of the global settlement agreement.

Generated by AI

Sentiment

Of the messages about ASND that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% new	88.89% -11.11	84.66% -15.25
Bearish	—	0% -100	11.11% +11.11	15.34% +15.25

Bullish· Sep 2

Ascendis Pharma A/S ($ASND) has been upgraded by JP Morgan to Overweight with a price target of 165.
The company's low float and upcoming app drop make it a strong buy opportunity.
Ascendis Pharma A/S is considered a sleeper rocket with significant potential for growth.

Bearish· Apr 3

Ascendis Pharma's ($ASND) stock has plummeted ~35% after the FDA found deficiencies in its TransCon application.
The FDA's negative statement has led to a significant sell-off, with some investors even questioning the 40% drop in value.
The company may need to raise cash in the near future due to the potential delay of its TransCon filing by at least a year or two.

Generated by AI

Topics

Of the messages about ASND that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	99.76%	79.01%
Analysts	—	0%	0%	7.74%
Earnings	—	0%	0%	3.66%
Technical Analysis	—	0%	0.24%	7.26%
Controversies	—	0%	0%	0.74%
Macro	—	0%	0%	1.59%

Earnings· Aug 29

Ascendis Pharma A/S reported a Q2 loss of $0.66, beating consensus estimates of a $1.03 loss.
The company reported Q2 GAAP EPS loss of €0.55 and revenue of €0.018M, a slight increase from €0.44M in Q2 2017.
$ASND stock dropped 1.20% following the release of Q2 results.

Analysts· Mar 15

Morgan Stanley raised Ascendis Pharma's price target to $197 from $180, maintaining an Overweight rating.
Bank of America upgraded Ascendis Pharma to Buy from Neutral, raising the price target to $161 from $148.
SVB Leerink analyst Joseph Schwartz raised the price target for Ascendis Pharma to $193 from $190, maintaining an Outperform rating.

Announcements· Sep 16

Ascendis Pharma's (ASND) TransCon trial achieved its primary objective, leading to a significant stock price increase.
The trial demonstrated that TransCon CNP (Navepegritide) showed superior results compared to a placebo, marking a crucial milestone for the company.
The pivotal ApproaCH trial's success has triggered a substantial pre-market price surge, with ASND stock rising by over 19% in early trading.

Generated by AI

Community

Of the messages about ASND, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	4%	33.91%	78.39%	72.8%
Newcomers	96%	66.09%	21.61%	27.2%

Regulars· Aug 17

The focus is on Druck's investment strategy, specifically his approach to biotech stocks like ASND.
Regulars are sharing their observations on Druck's track record, highlighting his strong performance in biotech investments.
One regular took a position in ASND before the launch metrics started to inflect, suggesting a positive outlook on the stock.

Newcomers· Feb 28

The FDA has approved Ascendis Pharma's (ASND) weekly therapy, Yuviwel, for pediatric achondroplasia, a rare form of dwarfism.
The approval is a major catalyst for ASND, with expected volatility and a potential increase in options flow.
ASND's approval is also being closely watched in the biotech sector, particularly with related stocks such as BBIO, as sector rotation and support levels are being monitored.

Generated by AI

Ascendis Pharma A/S

Social

Aug 31

Bullish· Sep 2

Bearish· Apr 3

Earnings· Aug 29

Analysts· Mar 15

Announcements· Sep 16

Regulars· Aug 17

Newcomers· Feb 28

Ascendis Pharma (ASND) Authorizes $400M Share Buyback

Ascendis Pharma (ASND) Regains Exclusive Rights To Key TransCon Metabolic Programs

Ascendis Pharma (ASND) Will Regain Metabolic Drug Rights. Is Greater Ownership Worth the Cost?

Ascendis Pharma: Back To Full Independence (NASDAQ:ASND)

Ascendis Has Capacity To Execute Alone After Termination of Novo Nordisk Collaboration, Wedbush Says

H.C. Wainwright reiterates Ascendis Pharma stock rating on Novo deal end

Also Discussed

Ascendis Pharma A/S

Company Information

Location

Ascendis Pharma (ASND) Authorizes $400M Share Buyback

Ascendis Pharma (ASND) Regains Exclusive Rights To Key TransCon Metabolic Programs

Ascendis Pharma (ASND) Will Regain Metabolic Drug Rights. Is Greater Ownership Worth the Cost?

Ascendis Pharma: Back To Full Independence (NASDAQ:ASND)

Ascendis Has Capacity To Execute Alone After Termination of Novo Nordisk Collaboration, Wedbush Says

H.C. Wainwright reiterates Ascendis Pharma stock rating on Novo deal end

Also Discussed

Social

Aug 31

Bullish· Sep 2

Bearish· Apr 3

Earnings· Aug 29

Analysts· Mar 15

Announcements· Sep 16

Regulars· Aug 17

Newcomers· Feb 28